Fabrizio Chiusolo

Dr. Fabrizio Chiusolo

Bambino Gesù Children's Hospital, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
RKRobinder G Khemani
Robinder G Khemani
LSLincoln Smith
Lincoln Smith
YLYolanda M Lopez-Fernandez
Yolanda M Lopez-Fernandez
JKJeni Kwok
Jeni Kwok
RMRica Morzov
Rica Morzov
JZJiri Zurek
Jiri Zurek

10 December 2019 in JAMA
Verified
Journal Article
Closed access
PSPhilip C. Spinella
Philip C. Spinella
MTMarisa Tucci
Marisa Tucci
DFDean A. Fergusson
Dean A. Fergusson
JLJacques Lacroix
Jacques Lacroix
PHPaul C. Hébert
Paul C. Hébert
ATAlexis F. Turgeon
Alexis F. Turgeon
The clinical consequences of red blood cell storage age for critically ill pediatric patients have not been examined in a large, randomized clinical trial. To determine if the transfusion of fresh red blood cells (stored ≤7 days) reduced new or progressive multiple organ dysfunction syndrome compared with the use of standard-issue red blood cells in critically ill children. The Age of Transfused Blood in Critically-Ill Children trial was an international, multicenter, blinded, randomized clinical trial, performed between February 2014 and November 2018 in 50 tertiary care centers. Pediatric patients between the ages of 3 days and 16 years were eligible if the first red blood cell transfusion was administered within 7 days of intensive care unit admission. A total of 15 568 patients were screened, and 13 308 were excluded. Patients were randomized to receive either fresh or standard-issue red blood cells. A total of 1538 patients were randomized with 768 patients in the fresh red blood cell group and 770 in the standard-issue group. The primary outcome measure was new or progressive multiple organ dysfunction syndrome, measured for 28 days or to discharge or death. Among 1538 patients who were randomized, 1461 patients (95%) were included in the primary analysis (median age, 1.8 years; 47.3% girls), in which there were 728 patients randomized to the fresh red blood cell group and 733 to the standard-issue group. The median storage duration was 5 days (interquartile range [IQR], 4-6 days) in the fresh group vs 18 days (IQR, 12-25 days) in the standard-issue group (P < .001). There were no significant differences in new or progressive multiple organ dysfunction syndrome between fresh (147 of 728 [20.2%]) and standard-issue red blood cell groups (133 of 732 [18.2%]), with an unadjusted absolute risk difference of 2.0% (95% CI, -2.0% to 6.1%; P = .33). The prevalence of sepsis was 25.8% (160 of 619) in the fresh group and 25.3% (154 of 608) in the standard-issue group. The prevalence of acute respiratory distress syndrome was 6.6% (41 of 619) in the fresh group and 4.8% (29 of 608) in the standard-issue group. Intensive care unit mortality was 4.5% (33 of 728) in the fresh group vs 3.5 % (26 of 732) in the standard-issue group (P = .34). Among critically ill pediatric patients, the use of fresh red blood cells did not reduce the incidence of new or progressive multiple organ dysfunction syndrome (including mortality) compared with standard-issue red blood cells. ClinicalTrials.gov Identifier: NCT01977547.

26 October 2022 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
DBDavid W. Brossier
David W. Brossier
LTLyvonne N. Tume
Lyvonne N. Tume
ABAnais R. Briant
Anais R. Briant
CCCorinne Jotterand Chaparro
Corinne Jotterand Chaparro
CMClémence Moullet
Clémence Moullet
T(The Metabolism Endocrinology And Nutrition Section Of The European Society Of Pediatric And Neonatal Intensive Care (Espnic)
The Metabolism Endocrinology And Nutrition Section Of The European Society Of Pediatric And Neonatal Intensive Care (Espnic)
Purpose Intravenous maintenance fluid therapy (IV-MFT) prescribing in acute and critically ill children is very variable among pediatric health care professionals. In order to provide up to date IV-MFT guidelines, the European Society of Pediatric and Neonatal Intensive Care (ESPNIC) undertook a systematic review to answer the following five main questions about IV-MFT: (i) the indications for use (ii) the role of isotonic fluid (iii) the role of balanced solutions (iv) IV fluid composition (calcium, magnesium, potassium, glucose and micronutrients) and v) and the optimal amount of fluid. Methods A multidisciplinary expert group within ESPNIC conducted this systematic review using the Scottish Intercollegiate Guidelines Network (SIGN) grading method. Five databases were searched for studies that answered these questions, in acute and critically children (from 37 weeks gestational age to 18 years), published until November 2020. The quality of evidence and risk of bias were assessed, and meta-analyses were undertaken when appropriate. A series of recommendations was derived and voted on by the expert group to achieve consensus through two voting rounds. Results 56 papers met the inclusion criteria, and 16 recommendations were produced. Outcome reporting was inconsistent among studies. Recommendations generated were based on a heterogeneous level of evidence, but consensus within the expert group was high. “Strong consensus” was reached for 11/16 (69%) and “consensus” for 5/16 (31%) of the recommendations. Conclusions Key recommendations are to use isotonic balanced solutions providing glucose to restrict IV-MFT infusion volumes in most hospitalized children and to regularly monitor plasma electrolyte levels, serum glucose and fluid balance.

15 August 2016 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
PDF file
FCFabrizio Chiusolo
Fabrizio Chiusolo
ADAntonella Diamanti
Antonella Diamanti
RBR. Bianchi
R. Bianchi
LFLucia Fusco
Lucia Fusco
MEM. Elia
M. Elia
SPS. Picardo
S. Picardo

1 September 2018 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
CGChiara Grimaldi
Chiara Grimaldi
FFFabrizio di Francesco
Fabrizio di Francesco
FCFabrizio Chiusolo
Fabrizio Chiusolo
Roberta AngelicoRoberta Angelico
Roberta Angelico
LMLidia Monti
Lidia Monti
JGJean de Ville de Goyet
Jean de Ville de Goyet

30 April 2015 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
TCTeresa Capriati
Teresa Capriati
SCSabrina Cardile
Sabrina Cardile
FCFabrizio Chiusolo
Fabrizio Chiusolo
FTFilippo Torroni
Filippo Torroni
PSPaolo Schingo
Paolo Schingo
ADAntonella Diamanti
Antonella Diamanti
Post-pyloric feeding (PF) allows the administration of enteral nutrition beyond the pylorus, either into the duodenum or, ideally, into the jejunum. The main indications of PF are: upper gastrointestinal tract obstructions, pancreatic rest (e.g., acute pancreatitis), gastric dysmotility (e.g., critically ill patients and chronic intestinal pseudo-obstruction) or severe gastroesophageal reflux with risk of aspiration (e.g., neurological disability). Physiological and clinical evidence derives from adults, but can also be pertinent to children. This review will discuss the practical management and potential clinical applications of PF in pediatric patients. Some key studies pertaining to the physiological changes during PF will also be considered because they support the strategy of PF management.